158 related articles for article (PubMed ID: 12201796)
1. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.
Aristides M; Chen J; Schulz M; Williamson E; Clarke S; Grant K
Pharmacoeconomics; 2002; 20(11):775-84. PubMed ID: 12201796
[TBL] [Abstract][Full Text] [Related]
2. Raltitrexed in colorectal cancer.
Drug Ther Bull; 1996 Oct; 34(10):78-80. PubMed ID: 8936802
[TBL] [Abstract][Full Text] [Related]
3. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
4. Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
[TBL] [Abstract][Full Text] [Related]
5. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
Norum J; Balteskard L; Edna TH; Laino R; Wählby L; Rønning G
J Chemother; 2002 Jun; 14(3):301-8. PubMed ID: 12120887
[TBL] [Abstract][Full Text] [Related]
6. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
7. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
Young A; Topham C; Moore J; Turner J; Wardle J; Downes M; Evans V; Kay S
Eur J Cancer Care (Engl); 1999 Sep; 8(3):154-61. PubMed ID: 10763646
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
Groener MG; van Ineveld BM; Byttebier G; van Hout BA; Rutten FF
Anticancer Drugs; 1999 Mar; 10(3):283-8. PubMed ID: 10327033
[TBL] [Abstract][Full Text] [Related]
9. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748
[No Abstract] [Full Text] [Related]
10. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
Popov I; Carrato A; Sobrero A; Vincent M; Kerr D; Labianca R; Raffaele Bianco A; El-Serafi M; Bedenne L; Paillot B; Mini E; Sanches E; Welch J; Collette L; Praet M; Wils J
Eur J Cancer; 2008 Oct; 44(15):2204-11. PubMed ID: 18707870
[TBL] [Abstract][Full Text] [Related]
11. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
12. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
Zalcberg J
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Wilson KS; Fitzgerald CA; Barnett JB; Gill S; Khoo KE
Cancer Invest; 2007 Dec; 25(8):711-4. PubMed ID: 18058467
[TBL] [Abstract][Full Text] [Related]
14. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
Ross P; Heron J; Cunningham D
Eur J Cancer; 1996; 32A Suppl 5():S13-7. PubMed ID: 8958037
[TBL] [Abstract][Full Text] [Related]
15. The costs of managing advanced colorectal cancer: a broad perspective.
Kerr DJ; O'Connor KM
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S23-6. PubMed ID: 9376634
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
Kerr DJ
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632
[TBL] [Abstract][Full Text] [Related]
18. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
Tsavaris N; Kosmas C; Vadiaka M; Kontos A; Fotia M; Angelopoulou A; Vrizidis N; Soulla M; Sougioultzis S; Koufos Ch
Invest New Drugs; 2002 Feb; 20(1):133-6. PubMed ID: 12003191
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of Raltitrexed ('Tomudex') in elderly patients with colorectal cancer.
Romiti A; Tonini G; Santini D; Di Seri M; Masciangelo R; Mezi S; Verì A; Santuari L; Vincenzi B; Brescia A; Marchei P; Frati L; Tomao S
Anticancer Res; 2002; 22(5):3071-6. PubMed ID: 12530045
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
